ModifiedUnitedHealthcarePolicy CS130.O

Virtual Upper Gastrointestinal Endoscopy

Policy governing the medical necessity and coverage stance for virtual upper GI endoscopy (3-D CT or 3-D MRI virtual endoscopy) for UnitedHealthcare commercial plans; defines applicability by state and summarizes evidence-based coverage rationale.

Policy Summary

PayerUnitedHealthcare

PolicyVirtual Upper Gastrointestinal Endoscopy

Policy CodePolicy CS130.O

Change TypeState applicability addedclinical evidence updated

Effective DateNov 1, 2025

Next Review Date

Key ActionDo not request coverage for virtual upper GI endoscopy as it is considered unproven and not medically necessary; follow plan-specific prior authorization requirements and use conventional endoscopy for biopsy when lesions are identified.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate this Medical Policy does not apply to the states of Nebraska and North Carolina; refer to the state-specific policy versions.

Updated Clinical Evidence section to reflect the most current information.

No RCTsrandomized controlled trials available

62esophageal varices study size

386MDCT upper GI bleeding study size

160gastric cancer staging study size

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

NE & NCstate exceptions noted

Coverage Criteria

Not medically necessary

Covered when ALL of the following are met:

Not medically necessary: Virtual upper GI endoscopy using 3-D CT or 3-D MRI is considered unproven and not medically necessary for detecting and evaluating upper GI lesions due to insufficient evidence of efficacy.

Supported by lack of randomized controlled trials and predominance of observational, small studies

This Medical Policy does not apply to the states listed in the Application section; refer to the state-specific policy or guideline where noted. Examples of states with their own virtual upper gastrointestinal endoscopy policies include Idaho, Kansas, Kentucky, Louisiana, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee. Follow the referenced state-specific policy when providing services to members in those states.

This Medical Policy does not apply to the states of Nebraska and North Carolina. Providers and payers should refer to the applicable state-specific policy versions for coverage determinations and prior authorization requirements in those states.

Virtual upper gastrointestinal endoscopy using three-dimensional (3-D) CT or 3-D MRI reconstructions is considered unproven and not medically necessary for detecting and evaluating upper GI lesions due to insufficient evidence of efficacy. The published literature is primarily observational, includes case reports and feasibility studies, and lacks randomized controlled trials and adequate comparative data to establish clinical utility; therefore these techniques are not supported for routine diagnostic use.

Coding and Product Codes

Applicable Codes (reference)CPT

76497	Unlisted computed tomography procedure (e.g., diagnostic, interventional).
76498	Unlisted magnetic resonance procedure (e.g., diagnostic, interventional)

Referenced FDA Product Codesmixed

JAK	FDA product code for imaging devices used to create virtual endoscopy images
LLZ	FDA product code for imaging devices used to create virtual endoscopy images
LNH	FDA product code for imaging devices used to create virtual endoscopy images

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for virtual upper GI endoscopy (virtual 3‑D CT/MRI endoscopy). Virtual procedures frequently billed with unlisted CT/MRI procedure codes (CPT 76497, 76498) are considered unproven and not medically necessary; submit prior authorization requests per the member's plan requirements and include clinical justification.

Prior authorization required — follow plan-specific prior authorization process and tools (e.g., InterQual)
If submitting, include clinical indication, prior evaluation, and rationale for imaging instead of conventional endoscopy

Denial Risk

Denial Risk for Virtual Upper GI Endoscopy

Virtual 3‑D CT/MRI endoscopy is considered unproven and not medically necessary for detection and evaluation of upper GI lesions. There is a risk of claim denial when virtual upper GI endoscopy (reported with unlisted codes such as 76497 or 76498) is billed as an alternative to conventional optical upper endoscopy.

Background

Virtual upper GI endoscopy (also described as virtual gastroscopy or virtual esophagography) is a noninvasive imaging technique that reconstructs the luminal surface of the esophagus, stomach, and proximal duodenum from volumetric CT or MRI data to provide a three-dimensional, endoluminal view without insertion of an endoscope or sedation. Proposed uses include evaluation for lesions such as varices, ulcers, precancerous changes, hernias, and preoperative staging of gastric malignancy. Limitations of the technique include lower fine-detail resolution compared with conventional optical endoscopy, radiation exposure when using CT-based protocols, and the inability to obtain tissue for biopsy; the available clinical evidence is limited to small observational studies and technical reports, and randomized controlled trials are lacking.

Definitions and Device Codes

Virtual upper gastrointestinal (GI) endoscopy — definition

DefinitionA noninvasive imaging procedure using 3‑D CT or 3‑D MRI reconstructions to visualize the inside surfaces of upper GI organs (esophagus, stomach, proximal duodenum) without endoscopic insertion; typically performed without anesthesia or sedation and cannot obtain biopsy specimens.

Primary imaging modalitiesThree‑dimensional computed tomography (3‑D CT) and three‑dimensional magnetic resonance imaging (3‑D MRI).

Anatomical targetsUpper gastrointestinal tract luminal surfaces including the esophagus, stomach, and proximal duodenum.

Clinical uses describedEvaluation of symptoms (nausea, reflux, abdominal pain, unexplained weight loss), detection of esophageal varices, inflammation, ulcers, precancerous conditions, hernias, and preoperative gastric cancer staging.

Key limitationsLower fine‑detail resolution than conventional endoscopy, radiation exposure with CT, and inability to perform biopsy (conventional endoscopy required if a lesion is found).

Policy Summary

PayerUnitedHealthcare

PolicyVirtual Upper Gastrointestinal Endoscopy

Policy CodePolicy CS130.O

Change TypeState applicability addedclinical evidence updated

Effective DateNov 1, 2025

Next Review Date

SourceLink

On This Page

Claims using unlisted CT/MRI codes for virtual endoscopy may be denied as not medically necessary

Note

Coverage Governed by Contract/State/Federal Terms

When determining coverage, reference the member's applicable federal, state, or contractual benefit plan terms. This policy is informational; if the benefit plan or law requires coverage that conflicts with this policy, the contractual/federal/state requirements govern.

Coverage decisions must reference applicable contract, state law, or federal requirements
This policy does not override plan-specific or regulatory coverage mandates

Prior Authorization

Follow-up Endoscopy Required for Lesions

If virtual imaging identifies a lesion, a conventional (optical) upper endoscopy is required for definitive diagnosis and tissue sampling (biopsy). Virtual endoscopy cannot obtain biopsy specimens.

Follow-up optical upper endoscopy required for biopsy and definitive diagnosis when a lesion is detected on virtual imaging

Documentation Required

Documentation Expectations

Document the clinical rationale and all relevant procedural details when requesting authorization or submitting claims for virtual upper GI endoscopy. Include the imaging modality and protocol, indication and symptoms, prior testing and results, comparative rationale for virtual vs conventional endoscopy, and whether conventional endoscopy is planned if a lesion is suspected. If using unlisted procedure codes, provide supporting documentation and operative/technical details to allow medical review.

Include imaging modality (CT or MRI), protocol and technical parameters
List clinical indication, prior evaluations, and relevant test results
If billing unlisted codes (76497, 76498), attach detailed imaging and procedural notes for review
State whether conventional optical endoscopy and biopsy are planned if abnormalities are identified

Note

Follow Plan‑Specific Prior Authorization and Tools

This policy provides interpretation guidance for UnitedHealthcare standard benefit plans and is informational. Use plan-specific tools (e.g., InterQual) and confirm member-specific prior authorization and coverage requirements before scheduling or performing services.

Confirm and follow the member's plan prior authorization and coverage requirements
Use UnitedHealthcare and third‑party utilization management tools as applicable

Imaging device product codes (FDA)

FDA product codesJAK — product code classification for imaging devices used to create virtual endoscopy images.

FDA product codesLLZ — product code classification for imaging devices used to create virtual endoscopy images.

FDA product codesLNH — product code classification for imaging devices used to create virtual endoscopy images; specific device indications should be verified via FDA 510(k) records.